Lebanon Pharmacy Colloquium study materials
Lebanon Pharmacy Colloquium study resources

Pediatric Spironolactone Suspension: Dose, Formulation, and Counseling

Lebanon Pharmacy Colloquium · Put your knowledge to work in context.

All case studies

Pediatric Spironolactone Suspension: Dose, Formulation, and Counseling

Rania is a 4-year-old girl weighing 14 kg who is discharged from a Beirut hospital with a new prescription for spironolactone 1.5 mg/kg/day in two divided doses for heart failure. The family arrives at your community pharmacy on a Friday evening with no medicine at home. Only spironolactone 25 mg tablets are in stock; the hospital's outpatient supply is empty and the imported pediatric suspension is unavailable nationwide. The parents say Rania cannot swallow tablets, and her mother asks whether a kitchen teaspoon is acceptable. You have a small compounding area with a mortar and pestle, graduated cylinders, an electronic balance, and two commercial oral suspending vehicles: one sucrose-based and one sugar-free preserved with parabens. The prescription is for 30 days. Her last potassium was 4.9 mmol/L and creatinine was normal. The pharmacy closes in 45 minutes and the parents are anxious.

1. Calculate Rania's dose, choose a concentration for an extemporaneous suspension, and state how much you will prepare and dispense. Show the arithmetic and justify the concentration you selected.

Read the worked answer

Dose calculation

  • 1.5 mg/kg/day × 14 kg = 21 mg/day
  • Divided twice daily = 10.5 mg per dose

Why tablets alone cannot solve this

A 25 mg tablet cannot be divided reliably into 10.5 mg. A half tablet is 12.5 mg and a quarter is 6.25 mg; either would misdose a small child with heart failure by 20–40%, and splitting uncoated tablets is imprecise.

Concentration choice

A concentration of 3 mg/mL gives 10.5 mg in 3.5 mL. That volume is easy to measure accurately in a 5 mL oral syringe with 0.5 mL graduations. By contrast:

  • 2 mg/mL would require 5.25 mL, which is awkward and less accurate.
  • 5 mg/mL would require 2.1 mL, a small volume in which a 0.1 mL error is a 5% dose error.

So 3 mg/mL balances accuracy, measurable volume, and a reasonable bottle size.

Quantity to prepare

  • 21 mg/day × 30 days = 630 mg
  • 630 mg ÷ 3 mg/mL = 210 mL
  • Add about 10–15% overage for loss during compounding and dosing: prepare 250 mL, containing 750 mg, or 30 tablets of 25 mg.

Dispensing

Label clearly with the concentration, dose volume, date prepared, beyond-use date, and storage instructions. Supply an oral syringe and demonstrate its use; do not rely on a teaspoon.

2. Select a suspending vehicle, assign a beyond-use date, and identify one formulation pitfall you must control. Justify each decision rather than simply stating a standard.

Read the worked answer

Vehicle selection

Spironolactone is practically insoluble in water and is light-sensitive, so it must be suspended, not dissolved. I would choose the sugar-free vehicle preserved with parabens for a young child: it avoids sucrose-related dental harm and provides a preserved aqueous base. The vehicle must be compatible with the drug and with the tablet excipients; if the manufacturer provides a validated suspension vehicle with published stability data for spironolactone, that is preferable to an uncharacterized base.

Beyond-use date

Without validated stability data for this exact drug–vehicle combination, I would assign a conservative 14-day refrigerated beyond-use date. Extemporaneous aqueous suspensions carry microbial risk, and a paraben system is not a guarantee against contamination during repeated use. If a published stability study for the same vehicle supports 30 days, I would use that date and document the reference. The key reasoning is that the beyond-use date must rest on evidence for the actual formulation, container, and storage conditions-not on the expiry date of the tablets.

Formulation pitfall

Spironolactone tablets contain insoluble excipients such as talc and magnesium stearate. If the powder is not triturated finely and suspended uniformly, the child can receive too little drug at the start of the bottle and too much at the end. I would:

  1. Triturate the tablets to a fine, uniform powder.
  2. Incorporate the powder into the vehicle by geometric dilution, not by dumping it into the whole volume.
  3. Avoid excessive foaming or heating.
  4. Package in an amber bottle and instruct the caregiver to shake vigorously before every dose.

I would also observe the final suspension for caking or phase separation before dispensing; if it does not resuspend, it should not be released.

3. List your counseling and monitoring plan, including what you will do about the potassium of 4.9 mmol/L. Explain how each point reduces a specific risk.

Read the worked answer

Counseling

  • Use the oral syringe, not a teaspoon. Household teaspoons vary from about 3 to 7 mL; at 3.5 mL per dose, that variation is clinically unacceptable.
  • Shake well before each dose. Spironolactone settles; shaking reduces dose variability.
  • Give with food to reduce gastrointestinal upset and to maintain consistent absorption.
  • Keep the bottle refrigerated and discard any remaining suspension after the assigned beyond-use date. Do not top up an old bottle with fresh suspension.
  • Do not use salt substitutes or potassium supplements. Spironolactone is potassium-sparing; the child is already at 4.9 mmol/L, near the upper limit.
  • Return promptly if she vomits, has diarrhea, or drinks poorly. Dehydration plus spironolactone can precipitate hyperkalemia and renal impairment.
  • Teach warning signs: muscle weakness, palpitations, unusual tiredness, or reduced urine output should prompt medical review.

Monitoring

The potassium of 4.9 mmol/L is within the reference range but high enough that I would not ignore it. I would:

  1. Contact the prescriber to report the baseline potassium and the planned starting dose.
  2. Recommend a repeat potassium and creatinine within 1–2 weeks of starting therapy, and sooner if the child becomes unwell.
  3. Ask about other potassium-containing products, including some rehydration solutions and herbal preparations.

Documentation

I would document the calculation, concentration, vehicle, beyond-use date, lot numbers, and counseling in the patient record, and give the caregiver written instructions in Arabic. A follow-up phone call after a few days would check technique and tolerance.